Briefly, most breast cancer patients were diagnosed for ductal invasive carcinoma (76%) at clinical stage 0 or 1 (80%) with a good prognostic grade (84% of grades I and II), 100% being RH+ and HER2−. This evidence concerns the gene ERBB2 and breast carcinoma.